Sugi Predict

Sugi Predict / Compounds / SCHEMBL292136

SCHEMBL292136

SCHEMBL292136

C[CH]c1nc2ccccc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 1/20 0.51
▸ HDAC3 O15379 1/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51
▸ HDAC8 Q9BY41 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ HDAC9 Q9UKV0 1/20 0.51
▸ HDAC5 Q9UQL6 1/20 0.51
▸ MAPT P10636 4/20 0.48
▸ NPC1 O15118 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ PSMB8 P28062 1/20 0.46
▸ ADAMTS5 Q9UNA0 1/20 0.45
▸ TP53 P04637 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421501 0.83 SNCA (0.64) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL6421503 0.83 SNCA (0.64) SNCAHDAC3HDAC4HDAC1HDAC7
Benzoxazolinone SCHEMBL31124589 0.80 HDAC3 (0.56) SNCAHDAC3HDAC4HDAC1HDAC7
Benzoxazolinone SCHEMBL140087 0.80 HDAC3 (0.56) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL3083787 0.79 SNCA (0.51) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL717591 0.79 SNCA (0.51) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL223564 0.79 HDAC3 (0.56) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL717590 0.79 SNCA (0.51) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL6598835 0.79 HDAC3 (0.56) SNCAHDAC3HDAC4HDAC1HDAC7
SCHEMBL28853114 0.79 MAPT (0.55) SNCAHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111511465-B Method for producing organic silicon dioxide material and use thereof 埃克森美孚科技工程公司 2023-06-06 — — CN disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 — — US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 — — US disclosed
US-11325111-B2 Catalysts and methods of making the same EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) 2022-05-10 — — US disclosed
CN-109311001-B Organosilica polymer catalyst and method for producing same 埃克森美孚研究工程公司 2022-04-08 — — CN disclosed
US-11111352-B2 Methods of producing organosilica materials and uses thereof EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2021-09-07 — — US disclosed
CN-107001945-B Aromatic hydrogenation catalyst and use thereof 埃克森美孚研究工程公司 2020-12-18 — — CN disclosed
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2020-11-19 — — US disclosed
EP-3727677-A1 METHODS OF PRODUCING ORGANOSILICA MATERIALS AND USES THEREOF ExxonMobil Research and Engineering Company (US) 2020-10-28 — — EP disclosed
EP-0838471-A1 PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST SAGAMI CHEMICAL RESEARCH CENTER (JP) 1998-04-29 — — EP disclosed
US-5616586-A Tricyclic quinoxalinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-04-01 — — US disclosed
WO-1996040141-A1 4,5-BRIDGED QUINOXALINEDIONES AND QUINOLONES AND THE USE THEREOF AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1996-12-19 — — WO disclosed
EP-0642508-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1995-03-15 — — EP disclosed
WO-1993008188-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1993-04-29 — — WO disclosed
US-4576753-A MICROBIOCIDES, ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-03-18 — — US disclosed
US-4472309-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 — — US disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 — — US disclosed
US-4264498-A REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-28 — — US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 SNCA 1213/4885HDAC3 51/4885HDAC4 79/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 SNCA 1213/4885HDAC3 51/4885HDAC4 79/4885
US-11325111-B2 Catalysts and methods of making the same CAT, STOM, SOD1 SNCA 171/4885HDAC3 1311/4885HDAC4 494/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 SNCA 1838/4885HDAC3 50/4885HDAC4 79/4885
US-20200361896-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 SNCA 1838/4885HDAC3 50/4885HDAC4 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.